Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010.

Lamb KE, Flasche S, Diggle M, Inverarity D, Greenhalgh D, Jefferies JM, Smith A, Edwards GF, Denham B, McMenamin J, McDonald E, Mitchell TJ, Clarke SC, Robertson C.

Vaccine. 2014 Jul 23;32(34):4356-63. doi: 10.1016/j.vaccine.2013.05.079. Epub 2013 Jun 24.

2.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
3.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

PMID:
18627249
4.
5.

Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.

Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health.

Pediatr Infect Dis J. 2010 Apr;29(4):289-93. doi: 10.1097/INF.0b013e3181c15471.

PMID:
19935447
6.

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance Team.

Vaccine. 2013 May 24;31(22):2572-7. doi: 10.1016/j.vaccine.2013.03.049. Epub 2013 Apr 11.

PMID:
23583813
7.

Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.

van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R.

Vaccine. 2012 Aug 31;30(40):5880-5. doi: 10.1016/j.vaccine.2012.06.068. Epub 2012 Jul 4.

PMID:
22771186
9.

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG; Toronto Bacterial Diseases Network; Canadian Public Health Laboratory Network.

Can J Microbiol. 2013 Dec;59(12):778-88. doi: 10.1139/cjm-2013-0614. Epub 2013 Oct 21.

PMID:
24313450
10.

Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.

Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.

Clin Infect Dis. 2017 Jan 15;64(2):175-183. doi: 10.1093/cid/ciw720. Epub 2016 Oct 21.

PMID:
27986682
11.

Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.

Rosen JB, Thomas AR, Lexau CA, Reingold A, Hadler JL, Harrison LH, Bennett NM, Schaffner W, Farley MM, Beall BW, Moore MR; CDC Emerging Infections Program Network.

Clin Infect Dis. 2011 Jul 15;53(2):137-43. doi: 10.1093/cid/cir326.

PMID:
21690620
12.

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.

Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks.

Vaccine. 2015 Jan 3;33(2):359-66. doi: 10.1016/j.vaccine.2014.11.011. Epub 2014 Nov 20.

PMID:
25448105
13.

Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.

Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW.

Clin Infect Dis. 2009 Jul 15;49(2):205-12. doi: 10.1086/599827.

PMID:
19508165
14.

Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.

Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.

Pediatr Infect Dis J. 2013 Jun;32(6):604-9. doi: 10.1097/INF.0b013e318287fe0d.

PMID:
23348816
15.

Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.

Wagenvoort GH, Sanders EA, Vlaminckx BJ, de Melker HE, van der Ende A, Knol MJ.

Euro Surveill. 2017 Mar 9;22(10). pii: 30481. doi: 10.2807/1560-7917.ES.2017.22.10.30481.

16.

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR; Active Bacterial Core Surveillance/Emerging Infections Program Network.

J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.

PMID:
19947881
17.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
18.
19.

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.

van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E.

Vaccine. 2014 Jul 23;32(34):4349-55. doi: 10.1016/j.vaccine.2014.03.017. Epub 2014 Mar 21.

PMID:
24657717
20.

Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland.

Clarke SC, Jefferies JM, Smith AJ, McMenamin J, Mitchell TJ, Edwards GF.

J Clin Microbiol. 2006 Apr;44(4):1224-8.

Supplemental Content

Support Center